药师主导减停抗胆碱能及镇静药物对社区衰弱老年人多重用药的随机对照试验
该实用型两臂随机对照试验纳入363例≥65岁社区老年人,按衰弱程度分层,比较常规照护与药师向全科医生提供减停建议的干预。结果显示,干预组与对照组在6个月内药物负担指数(DBI)下降≥0.5的比例分别为12.2%和12.7%,差异无统计学意义,未发现干预有效的证据。
要点
- 药师主导的减停建议未能在6个月内降低衰弱老年人的抗胆碱能/镇静药物负荷。
- 干预组DBI下降≥0.5的比例为12.2%,对照组为12.7%,差异无统计学意义。
- 各衰弱分层均未观察到干预有效的证据。
核心结论
- 药师主导的药物审查未能减少衰弱老年参与者在6个月内的抗胆碱能/镇静药物负荷。
研究设计与样本
- 实用型两臂随机对照试验,按衰弱程度分层,比较常规照护与药师向全科医生提供减停建议的干预。
- 从新西兰两个地区卫生局招募≥65岁社区老年人,经标准化interRAI需求评估后纳入。
- 使用药物负担指数(DBI)量化每位参与者的镇静及抗胆碱能药物使用。
- 试验按低、中、高衰弱程度分层。
主要发现
- 363例参与者中,对照组21例(12.7%)、干预组21例(12.2%)在6个月内DBI下降≥0.5。
- 比例差异为-0.4%(95%CI:-7.9%至7.0%),无干预有效的证据。
- 任何衰弱水平的参与者均无证据提示该干预有效。
- COVID-19封锁措施要求对干预进行修改,封锁前后亚组分析显示对结局无影响。
临床怎么用
- 药师主导的减停建议策略在类似情境下可能不足以降低衰弱老年人的抗胆碱能/镇静药物负荷。
- 从实施科学角度审视本试验及其他减停试验,有助于理解阻碍或促成减停实施策略成功的背景因素。
局限性
- COVID-19封锁措施要求修改干预方案。
- 未报告样本量计算、P值等详细信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polypharmacy is associated with poor outcomes in older adults. Targeted deprescribing of anticholinergic and sedative medications may improve health outcomes for frail older adults. Our pharmacist-led deprescribing intervention was a pragmatic 2-arm randomized controlled trial stratified by frailty. We compared usual care (control) with the intervention of pharmacists providing deprescribing recommendations to general practitioners. METHODS: Community-based older adults (≥65 years) from 2 New Zealand district health boards were recruited following a standardized interRAI needs assessment. The Drug Burden Index (DBI) was used to quantify the use of sedative and anticholinergic medications for each participant. The trial was stratified into low, medium, and high-frailty. We hypothesized that the intervention would increase the proportion of participants with a reduction in DBI ≥ 0.5 within 6 months. RESULTS: Of 363 participants, 21 (12.7%) in the control group and 21 (12.2%) in the intervention group had a reduction in DBI ≥ 0.5. The difference in the proportion of -0.4% (95% confidence interval [CI]: -7.9% to 7.0%) provided no evidence of efficacy for the intervention. Similarly, there was no evidence to suggest the effectiveness of this intervention for participants of any frailty level. CONCLUSION: Our pharmacist-led medication review of frail older participants did not reduce the anticholinergic/sedative load within 6 months. Coronavirus disease 2019 (COVID-19) lockdown measures required modification of the intervention. Subgroup analyses pre- and post-lockdown showed no impact on outcomes. Reviewing this and other deprescribing trials through the lens of implementation science may aid an understanding of the contextual determinants preventing or enabling successful deprescribing implementation strategies.
引用
- Jamieson H, Nishtala PS, Bergler HU, et al. Deprescribing Anticholinergic and Sedative Drugs to Reduce Polypharmacy in Frail Older Adults Living in the Community: A Randomized Controlled Trial. J Gerontol A Biol Sci Med Sci. 2023. PMID: 36692224. doi:10.1093/gerona/glac249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。